Stoke Therapeutics, Inc. 8-K

What Happened

• On January 21, 2026, Stoke Therapeutics, Inc. announced it entered into a lease with NWALP PHOP Property Owner LLC for approximately 98,500 square feet at 245 Fifth Avenue, Waltham, Massachusetts to expand its corporate headquarters and laboratory space. The lease runs through March 31, 2038 and the Company filed the arrangement in an 8-K on January 26, 2026. A copy of the Lease Agreement will be included as an exhibit to Stoke’s Form 10-Q for the quarter ended March 31, 2026.

Key Details

• Lease date: January 21, 2026; filing date: January 26, 2026.
• Premises: ~98,500 sq ft at 245 Fifth Avenue, Waltham, MA.
• Term: Expires March 31, 2038, with two options to extend for 5 years each at prevailing market rates.
• Estimated aggregate base rent over the term: ≈ $85.5 million.
• Security deposit: $3.0 million provided as an irrevocable standby letter of credit (may be reduced per lease terms).
• Reported under Item 1.01 (material definitive agreement) and Item 2.03 (creation of a direct financial obligation).

Why It Matters

• The lease secures significant long-term office and lab capacity, supporting Stoke’s operational and R&D needs.
• It also creates a substantial, multi-year fixed obligation (≈ $85.5M) and a $3M letter-of-credit commitment that investors should consider when assessing the company’s future cash needs and lease-related liabilities.
• The terms (long duration and extension options) reduce short-term relocation risk but increase long-term fixed costs; the full lease will be available for review in the upcoming 10-Q for more detail.